According to the latest market research report on the Biopharmaceutical Excipient Manufacturing Market, published by IndustryARC, The Biopharmaceutical Excipient Manufacturing Market size is forecast to reach USD 5,888.0 Million by 2035, after growing at a CAGR of 4.9% during 2023-2035. The major driving forces of this market are increasing incidences of chronic diseases owing to sedentary lifestyles; substantial investments by pharmaceutical companies in the development of medicines; and the implementation of new techniques such as nanotechnology.
The Biopharmaceutical Excipient Manufacturing Market research report is segmented Distribution by Type of Excipient based on Chemical Composition (Carbohydrates, Polyols, Polymers, Proteins / amino acids, Salts, Lipids, Others), Distribution by Type of Excipient based on Function (Surfactants, Stabilizers, Tonicity modifiers, Bulking agents, Buffering agents, Solubility enhancers, Drug delivery system, Chelators, Antimicrobials, Antioxidants, and Others), Distribution by Type of Excipient based on Chemical Structure (Organic, Inorganic), Distribution by Scale of Operation: (Preclinical, Clinical, Commercial), Distribution by Type of Biologic: (Vaccines, Proteins/peptides, Cell therapies, Antibodies, Blood products), Distribution by Company Size: (Small, Mid-sized, Large, Very Large), By Geography(North America, Europe, Asia, South America, MENA, Rest of World). which provides a comprehensive analysis of global market & industry forecast (2023 – 2035).
Request Sample Research Report: https://www.industryarc.com/pdfdownload.php?id=16327
Europe Anticipated to Show the Fastest Growth in the Market:
Europe Biopharmaceutical Excipient Manufacturing Market generated a revenue of $1.03 Million in 2022 and is projected to reach a revenue of $1.76 Million by 2035 growing at a CAGR of 4.1% during 2023-2035. By promoting the best use of excipients in medications, the International Pharmaceutical Excipients Council (IPEC) Europe produces standards to improve patient safety.
Since 1992, IPEC Europe has brought together manufacturers, distributors, and users of pharmaceutical excipients. Because of rising healthcare costs and an aging population, Europe’s pharmaceutical industry is booming. This rise fuels the demand for pharmaceutical excipients, which are used to create new medications and improve current ones. Excipients in biopharmaceuticals play an important role in increasing medication stability, solubility, and bioavailability. Drug formulation processes and excipient functions are constantly improving, which drives market expansion.
Biopharmaceutical Excipient Manufacturing Market 2023-2035: Scope of the Report
|
Report Metric |
Details |
|
Base Year Considered |
2022 |
|
Forecast Period |
2023–2035 |
|
CAGR |
3.44% |
|
Market Size in 2035 |
$675million |
|
Segments Covered |
Distribution by Type of Excipient based on Chemical Composition, Function, Chemical Structure, Distribution by Scale of Operation, Distribution by Type of Biologic, Distribution by Company Size, and Region |
|
Geographies Covered |
North America, Europe, Asia, South America, MENA, Rest of World |
|
Key Market Players |
|
Get Access to the Full Research Report: https://www.industryarc.com/Report/16327/pharmaceutical-excipients-market.html
Biopharmaceutical Excipient Manufacturing Market Report – Key Takeaways:
Antimicrobialsis Leading the Market
Based on functions, Antimicrobials held the major market share of 24% in 2022. The antimicrobials sector is predicted to grow rapidly in the next years. The change in growth trajectory is primarily due to enterprises restarting production during the COVID-19 epidemic, when demand soared significantly. The worldwide antimicrobials market is expected to rise significantly as coronavirus spreads. Furthermore, the increasing prevalence of bacterial infections would need the introduction of antimicrobials into the market.
Proteins/Amino Acids dominated the Biopharmaceutical Excipient Manufacturing Market
In 2022, proteins and amino acids dominated the Biopharmaceutical Excipient Manufacturing Market. This is attributable to increased consumer spending power and increased individual understanding of preventative care and healthy lifestyles. They are used in health supplements to reduce muscle soreness and fatigue as well as the risk of cardiovascular disease. Plant-based protein sources are in high demand due to the popularity of veganism and vegetarianism. Because plant-based proteins typically lack one or more critical amino acids, amino acid supplements are used to ensure that those following a plant-based diet receive adequate nutrition.
Growing pharmaceutical drug demand is predicted to drive the organic biopharmaceutical excipients market forward
Pharmaceutical medications are chemical substances or compounds that are used in humans to prevent, diagnose, treat, or relieve a variety of diseases, medical conditions, or symptoms. The rising need for pharmaceutical treatments has increased the demand for organic pharmaceutical excipients, which serve as acceptable and compatible ingredients in organic drug formulations and aid in the drug’s physiological absorption. Global medicines production climbed by 4.6 percent in June 2022, according to the European Federation of Pharmaceutical Industries and Associations, a European pharmaceutical industry body, from €286,697 million ($308,881 million) in 2020 to €300,000 ($323,214) in 2021.
Manufacturing complexity Hinder the Market
Some biopharmaceutical excipients, such as lipids, have sophisticated and capital-intensive manufacturing procedures. As a result, demand for pharmaceutical excipients for biologics has increased significantly. However, the accompanying manufacturing procedures for some biopharmaceutical excipients, such as lipids, are highly sophisticated, capital-intensive, and fraught with several problems. Excipient variability, excipient concentrations, capital-intensive manufacturing procedures, multiple difficulties, viscosity, analytical characterisation, and isotonic formulations can all contribute to the complexity of biopharmaceutical excipient manufacturing.
Purchase this Premium Report: https://www.industryarc.com/purchasereport.php?id=16327
Key Opportunity Analysis:
The growing emphasis of pharmaceutical companies on the generic market
Key market participants are concentrating on the development and commercialization of innovative biopharmaceutical excipients. DFE Pharma, for example, released a new excipient product line called ‘BioHale’ in April 2021 to address global supply difficulties for biopharmaceutical businesses. Furthermore, as demand for biopharmaceutical excipients grows, manufacturing facilities are expanding geographically. For example, in May 2022, DFE Pharma launched a new facility in India to provide pharmaceutical players with fast-track formulation services, including excipients, to obtain the proper formulations.
Multifunctional excipients are becoming more popular
Industry acceptance of multi-functional biopharmaceutical excipients is also driving market expansion. They are efficient and effective in improving the biopharmaceutical manufacturing process. Better product quality, increased production, and lower operational costs are all associated benefits. The success of COVID-19 vaccines is mostly dependent on their effectiveness, which has been improved by the use of efficient drug delivery systems; this provides enormously lucrative potential for market entities. Multifunctional excipients such as Ludiflash, F-MELT, and Avicel CE-15 have been created specifically for ODT formulations.
Growing Opportunities and R&D Activities for Major Companies
When it comes to huge business size in the biopharmaceutical excipient market, various aspects come into play. Because of their vast medication portfolios and production scale, large pharmaceutical companies often have a higher demand for excipients. Kerry Group, Avantor, Lubrizol Corp, BASF, Roquette Freres, FMC Corp, Croda International, Ashland Global Holdings, and ABITEC are examples of mid-sized biopharmaceutical excipient manufacturers. These companies frequently conduct considerable research and development operations, which results in the manufacturing of numerous biopharmaceutical medications that require various excipients.
If you have any questions, please feel free to contact our experts at: https://www.industryarc.com/reports/request-quote?id=16327
The Report also Covers the Following Areas:
- Biopharmaceutical Excipient Manufacturing Market Size and Forecast
- Biopharmaceutical Excipient Manufacturing Market Trends
- Biopharmaceutical Excipient Manufacturing Market Analysis by Type
Biopharmaceutical Excipient Manufacturing Market 2022-2035: Key Highlights
- CAGR of the market during the forecast period 2023-2035
- Value Chain analysis of key stakeholders
- Detailed analysis of market drivers and opportunities during the forecast period
- Biopharmaceutical Excipient Manufacturing market size estimation and forecast
- Analysis and predictions on end users’ behavior and upcoming trends
- Competitive landscape and Vendor market analysis including offerings, developments, and financials
- Comprehensive analysis of challenges and constraints in the Biopharmaceutical Excipient Manufacturing Market
Covid and Ukrainian Crisis Impact:
- The COVID-19 pandemic has caused significant disruptions in global supply chains which has impacted the availability and cost of raw materials as well as the transportation of finished products. This has resulted in increased lead times, reduced production, and higher costs. Additionally, the pandemic has caused delays in investment in new capacity and infrastructure which could impact the long-term supply and demand dynamics in the market.
- The Ukraine and Russia conflict led to an increase in prices and a reduction in production which further led to a shortage of Biopharmaceutical Excipient Manufacturing. Many companies have shut business in Russia; temporarily shutting down their plants in Ukraine. Additionally, the crisis in Ukraine has also led to a reduction in investments in the Biopharmaceutical Excipient Manufacturing market as companies are hesitant to invest in a region that is facing political and economic instability. This could impact the long-term supply and demand dynamics of the market.
To Get a Customized Industry Analysis, Speak with our Research Analyst: https://connect.industryarc.com/lite/schedule-a-call-with-our-sales-expert
List of Top Companies in the Biopharmaceutical Excipient Manufacturing Market:
The Global Biopharmaceutical Excipient Manufacturing Market is moderately concentrated as the majority share is held by the leading Biopharmaceutical Excipient Manufacturing providers. The key companies profiled are listed below:
- Cargill Inc
- ADM Company
- Merck
- Evonik
- DuPont
- IFF Inc
- Kerry Group
- Avantor
- Lubrizol Corp
- BASF
- Roquette Freres
- FMC Corp
- Croda International
- Ashland Global Holdings
- ABITEC
Related Reports:
Pharmaceutical Excipients Market – The Pharmaceutical Excipients Market is expected to reach US$11.1 billion by 2028, increasing at a CAGR of 6.2% between 2023 and 2028. Pharmaceutical excipients are compounds other than active pharmaceutical ingredients (API) that have been carefully examined for safety and are purposely included for the goal of drug distribution throughout the body.
Biologic Excipients Market – Excipients for Biologics The market was valued at $1,089 million in 2020 and is expected to reach $1,685 million by the end of 2026, rising at a CAGR of 5.8% between 2021 and 2026. The rapid rise of the biologic excipients sector is ascribed to the urgent need for the development of effective vaccines, the presence of a large pharmaceutical industry, and the creation of new market prospects.
Biopharmaceuticals Market – The Biopharmaceuticals Market is expected to reach $550.2 billion by 2028, increasing at a 7.4% CAGR between 2023 and 2028. Biopharmaceuticals are compounds that can be created using live creatures, such as microbes and animal cells, and are intended for therapeutic application in medicines.
Remicade Biosimilar Market – The global market for remicade biosimilars is being driven by primary factors such as the development of efficient and advanced technology, increased patent expiration, increased public awareness of remicade biosimilars, increased government initiatives around the world, and the growing prevalence of chronic diseases among the aging population. Furthermore, increased remicade biosimilar use in emerging economies such as China, India, and others would generate new opportunities for the worldwide remicade biosimilar market. However, increasing R&D costs and severe government regulations are the primary limitations for the global remicade biosimilar market.
About IndustryARC™:
IndustryARC primarily focuses on Market Research and Consulting Services specific to Cutting Edge Technologies and Newer Application segments of the market. The company’s Custom Research Services are designed to provide insights into the constant flux in the global demand-supply gap of markets.
IndustryARC’s goal is to provide the right information required by the stakeholder at the right point in time, in a format that assists an intelligent and informed decision-making process.
Contact Us:
Mr. Venkat Reddy
IndustryARC
Email: [email protected]
USA: (+1) 518 282 4727
Web: https://www.industryarc.com
Follow us on:LinkedIn | Facebook | Twitter
Contact Information:
Mr. Venkat Reddy IndustryARC Email: [email protected] USA: (+1) 518 282 4727
Tags:
BNN, Extended Distribution, iCN Internal Distribution, Research Newswire, English